摘要
原发性硬化性胆管炎(primary sclerosing cholangitis,PSC)是一种以肝内外胆管破坏、炎症和纤维化为特征的慢性胆汁淤积性肝病。多数患者会进展为肝硬化和终末期肝病。本文概述了PSC的药物治疗进展,认为多种治疗PSC的药物处于临床试验阶段并初步显示出应用前景,但目前尚无有效药物上市,多数患者最终需要进行肝移植。
Primary sclerosing cholangitis （PSC） is a chronic cholestatic liver condition characterized by inflamma- tion, fibrosis, and destruction of the intra- and extra-hepatic bile ducts. It progresses to biliary cirrhosis and end-stage liver disease in a majority of patients. In this paper, the advance in drug therapy of PSC was reviewed. Many drugs have been extensively studied in clinical trials and show good perspective. Currently, there is no effective medical therapy for PSC, and the majority of patients will eventually require liver transplantation.
出处
《胃肠病学和肝病学杂志》
CAS
2017年第11期1210-1212,共3页
Chinese Journal of Gastroenterology and Hepatology
基金
上海市科委"科技创新行动计划"医学与农业领域重点项目(13401902100)
上海市申康发展中心市级医院新兴前沿技术联合攻关项目(SHDC12015129)
关键词
原发性硬化性胆管炎
熊去氧胆酸
奥贝胆酸
药物治疗
Primary sclerosing cholangitis
Ursodeoxycholic acid
Obeticholic acid
Drug therapy
